Company Filing History:
Years Active: 2018
Title: Matko Kalac: Innovator in Cancer Treatment
Introduction
Matko Kalac is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of medical research, particularly in the development of compounds for the treatment of cancer and autoimmune disorders. His innovative work has led to the creation of a patent that addresses critical health challenges.
Latest Patents
Matko Kalac holds a patent for "N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation." This invention relates to the NQBS class of molecules, which have been observed to inhibit the nuclear translocation of NF-κB subunits. The patent outlines that this inhibition may occur through two mechanisms: either by binding to the C-terminus of the RHD, which mediates nuclear internalization, or by stabilizing the dimer/IκB complex, preventing the dissociation of active NF-κB monomers. The therapeutic applications of these molecules are significant, as they may be beneficial in treating various inflammatory states and diseases.
Career Highlights
Matko Kalac is affiliated with Columbia University, where he conducts research and collaborates with other experts in the field. His work has garnered attention for its potential impact on therapeutic strategies for serious health conditions.
Collaborations
Some of his notable coworkers include Donald W. Landry and Owen Anthony O'Connor. Their collaborative efforts contribute to advancing research in the medical field, particularly in the development of innovative treatments.
Conclusion
Matko Kalac's contributions to the field of cancer treatment through his patented inventions highlight the importance of innovation in medical research. His work at Columbia University and collaborations with esteemed colleagues further emphasize his commitment to improving health outcomes.